Abstract 447MO
Background
There is no optimal standard treatment for recurrent high grade glioma. However, even with aggressive treatment, the prognosis of recurrent high grade glioma is still poor. Anlotinib Hydrochloride is a novel small molecule multi-targeted tyrosine kinase receptor inhibitor (VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFRβ), which can effectively penetrate the blood-brain barrier. Currently, inhibition of tumour growth has been observed in a variety of tumours with significant efficacy with Anlotinib Hydrochloride. Previous literature indicated that targeting angiogenesis prolonged PFS, but was not effective in OS. This research project innovatively proposes Anlotinib Hydrochloride combined with temozolomide for the treatment of recurrent high grade glioma.
Methods
This trial is a prospective, open, single arm, phase II clinical study evaluating the safety and efficacy of the Anlotinib Hydrochloride combined with temozolomide in the treatment of recurrent high grade glioma. The primary objective is to evaluate the overall survival (OS) of patients. The secondary objectives are to evaluate the progression-free survival (PFS), objective remission rate (ORR), and safety of this regimen in patients with recurrent high grade glioma.
Results
A total of 94 patients were enrolled from 2020.4 to 2024.4, including 57 males and 37 females, with a mean age of 46 years. At the time of enrollment, the mean KPS of all patients was 72. The median OS was 8.97 months, PFS was 6.13 months, and ORR was 32.9%. A total of 40 cases of treatment-related AE occurred, including 10 cases of grade 3 or higher, no terminal AE occurred.
Conclusions
Anlotinib Hydrochloride combined with temozolomide was effective in prolonging recurrent high grade glioma patient survival, while treatment-related toxicity was acceptable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
445MO - Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
Presenter: Frank Giordano
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
446MO - SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
Invited Discussant 445MO, 446MO and 447MO
Presenter: Giuseppe Lombardi
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast
448MO - A clinical study of the safety and efficacy of toripalimab in combination with anilotinib for the treatment of recurrent glioblastoma (GBM)
Presenter: liang wang
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
449MO - Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results
Presenter: Fabio Ciceri
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
450MO - Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 448MO, 449MO and 450MO
Presenter: Dieta Brandsma
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast
451MO - Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Presenter: Maria Angeles Vaz Salgado
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
452MO - Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
Presenter: Estela Pineda
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
453MO - A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast